Article

Study: Lymph Nodes Supply Body With T Cells to Attack Cancer

Investigators used a new animal model to determine how the stem-like T cell can survive and what it looks like over the course of several months of tumor growth.

Investigators from the Yale Cancer Center have found that these immune system fighters can slow tumor growth.

T cells that contain certain lymph nodes could be natural cancer fighters, according to the results of a new study by the Yale Cancer Center.

“Therapies that use the immune system to destroy cancer have been a game-changer for patients with lung and other cancers,” Nikhil Joshi, PhD, assistant professor of immunobiology at the Center of Immuno-Oncology at Yale Cancer Center, said in a statement. “But not all people respond to immunotherapy drugs, so it was important for us to discover the role of these special T cells in tumor growth.”

Investigators used a new animal model to determine how the stem-like T cell can survive and what it looks like over the course of several months of tumor growth.

They discovered that the T cells cannot live for very long, which means that they must be resupplied from somewhere else, which seems to be the nearby lymph nodes, the statement said.

Investigators think that this is essential for slowing the grown of cancer, which could aid the response to immunotherapy, according to the statement.

Reference

Study shows stem-like T cells could aid immunotherapy in cancer treatment. EurekAlert. News release. September 3, 2021. Accessed September 7, 2021. https://www.eurekalert.org/news-releases/927356

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com